PMID- 15180471
OWN - NLM
STAT- MEDLINE
DCOM- 20040819
LR  - 20191108
IS  - 1568-010X (Print)
IS  - 1568-010X (Linking)
VI  - 3
IP  - 2
DP  - 2004 Jun
TI  - Targeting tumor necrosis factor-alpha in the therapy of psoriasis.
PG  - 175-83
AB  - Tumor necrosis factor-alpha (TNF-alpha) plays a fundamental role in the 
      initiation and persistence of skin inflammation in psoriasis. The best evidence 
      of the essential activity of this cytokine in the pathogenesis of psoriasis came 
      from the observation that selective TNF-alpha blockers are dramatically effective 
      in the therapy of this disease. The TNF-alpha inhibitors, infliximab and 
      etanercept, have been employed with success in moderate to severe psoriasis and 
      in psoriatic arthritis in randomized controlled trials. Anti-TNF-alpha 
      biologicals induce rapid disease resolution and long-lasting remission, 
      suggesting that they may alter the natural course of the disease. Further studies 
      are warranted to more precisely establish the biological bases of the action of 
      anti-TNF-alpha agents, better define which subgroup of patients can benefit most 
      from this treatment, and the modalities of combination therapy with other 
      antipsoriatic agents. Many other TNF-alpha inhibitors have been developed but 
      none of them has been yet used in the therapy of psoriasis. Major limitations to 
      the use of selective TNF-alpha blockers include the reactivation of latent 
      tuberculosis, the risk of opportunistic infections, the development of specific 
      antibodies, which is associated with a reduced duration of response to treatment, 
      and the high cost.
FAU - Gisondi, Paolo
AU  - Gisondi P
AD  - Istituto Dermopatico dell'Immacolata, IRCCS, Rome, Italy. p.gisondi@idi.it
FAU - Gubinelli, Emanuela
AU  - Gubinelli E
FAU - Cocuroccia, Barbara
AU  - Cocuroccia B
FAU - Girolomoni, Giampiero
AU  - Girolomoni G
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Netherlands
TA  - Curr Drug Targets Inflamm Allergy
JT  - Current drug targets. Inflammation and allergy
JID - 101160019
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - B72HH48FLU (Infliximab)
SB  - IM
MH  - Antibodies, Monoclonal/pharmacology/therapeutic use
MH  - Drug Delivery Systems/*methods
MH  - Humans
MH  - Infliximab
MH  - Psoriasis/*drug therapy/*metabolism
MH  - Tumor Necrosis Factor-alpha/antagonists & inhibitors/*metabolism
RF  - 81
EDAT- 2004/06/08 05:00
MHDA- 2004/08/20 05:00
CRDT- 2004/06/08 05:00
PHST- 2004/06/08 05:00 [pubmed]
PHST- 2004/08/20 05:00 [medline]
PHST- 2004/06/08 05:00 [entrez]
AID - 10.2174/1568010043343903 [doi]
PST - ppublish
SO  - Curr Drug Targets Inflamm Allergy. 2004 Jun;3(2):175-83. doi: 
      10.2174/1568010043343903.